Johnson & Johnson Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax
Johnson & Johnson (JNJ) reported Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax of $163.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax · last filed 2026-07-23
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for the quarter ending 2026-06-28 was $163.00M.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for the quarter ending 2026-03-29 was $213.00M.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for the quarter ending 2025-12-28 was -$71.00M, a 120.23% decline year-over-year.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for the quarter ending 2025-09-28 was $0.00.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for fiscal 2025 was -$1.19B, a 521.99% decline from fiscal 2024.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for fiscal 2024 was $282.00M.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for fiscal 2023 was -$131.00M, a 166.50% decline from fiscal 2023.
- Johnson & Johnson other comprehensive income (loss), derivative, excluded component, increase (decrease), before adjustments and tax for fiscal 2023 was $197.00M, a 49.10% decline from fiscal 2022.
| Period end | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax 3 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax 6 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax 9 month | Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax 12 month |
|---|---|---|---|---|
| 2026-06-28 | $163.00M 10-Q · filed 2026-07-23 | $376.00M 10-Q · filed 2026-07-23 | $305.00M derived: sum of 3 quarters · filed 2026-07-23 | $305.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-29 | $213.00M 10-Q · filed 2026-04-22 | $142.00M derived: sum of 2 quarters · filed 2026-04-22 | $142.00M derived: sum of 3 quarters · filed 2026-04-22 | -$661.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-28 | -$71.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$71.00M derived: sum of 2 quarters · filed 2026-02-11 | -$874.00M derived: sum of 3 quarters · filed 2026-07-23 | -$1.19B 10-K · filed 2026-02-11 |
| 2025-09-28 | $0.00 10-Q · filed 2025-10-22 | -$803.00M derived: sum of 2 quarters · filed 2026-07-23 | -$1.12B 10-Q · filed 2025-10-22 | -$768.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-29 | -$803.00M 10-Q · filed 2026-07-23 | -$1.12B 10-Q · filed 2026-07-23 | -$768.00M derived: sum of 3 quarters · filed 2026-07-23 | -$967.00M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-30 | -$316.00M 10-Q · filed 2026-04-22 | $35.00M derived: sum of 2 quarters · filed 2026-04-22 | -$164.00M derived: sum of 3 quarters · filed 2026-04-22 | -$118.00M derived: sum of 4 quarters · filed 2026-04-22 |
| 2024-12-29 | $351.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $152.00M derived: sum of 2 quarters · filed 2026-02-11 | $198.00M derived: sum of 3 quarters · filed 2026-02-11 | $282.00M 10-K · filed 2026-02-11 |
| 2024-09-29 | -$199.00M 10-Q · filed 2025-10-22 | -$153.00M derived: sum of 2 quarters · filed 2025-10-22 | -$69.00M 10-Q · filed 2025-10-22 | -$235.00M derived: sum of 4 quarters · filed 2025-10-22 |
| 2024-06-30 | $46.00M 10-Q · filed 2025-07-24 | $130.00M 10-Q · filed 2025-07-24 | -$36.00M derived: sum of 3 quarters · filed 2025-07-24 | $65.00M derived: sum of 4 quarters · filed 2025-07-24 |
| 2024-03-31 | $84.00M 10-Q · filed 2025-04-23 | -$82.00M derived: sum of 2 quarters · filed 2025-04-23 | $19.00M derived: sum of 3 quarters · filed 2025-04-23 | $30.00M derived: sum of 4 quarters · filed 2025-04-23 |
| 2023-12-31 | -$166.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$65.00M derived: sum of 2 quarters · filed 2025-02-13 | -$54.00M derived: sum of 3 quarters · filed 2025-02-13 | -$131.00M 10-K · filed 2025-02-13 |
| 2023-10-01 | $101.00M 10-Q · filed 2024-10-23 | $112.00M derived: sum of 2 quarters · filed 2024-10-23 | $35.00M 10-Q · filed 2024-10-23 | -$246.00M derived: sum of 4 quarters · filed 2024-10-23 |
| 2023-07-02 | $11.00M 10-Q · filed 2024-07-25 | -$66.00M 10-Q · filed 2024-07-25 | -$347.00M derived: sum of 3 quarters · filed 2024-07-25 | -$139.00M derived: sum of 4 quarters · filed 2024-07-25 |
| 2023-04-02 | -$77.00M 10-Q · filed 2024-05-01 | -$358.00M derived: sum of 2 quarters · filed 2024-05-01 | -$150.00M derived: sum of 3 quarters · filed 2024-05-01 | $52.00M derived: sum of 4 quarters · filed 2024-05-01 |
| 2023-01-01 | -$281.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | -$73.00M derived: sum of 2 quarters · filed 2024-02-16 | $129.00M derived: sum of 3 quarters · filed 2024-02-16 | $197.00M 10-K · filed 2024-02-16 |
| 2022-10-02 | $208.00M 10-Q · filed 2023-10-27 | $410.00M derived: sum of 2 quarters · filed 2023-10-27 | $478.00M 10-Q · filed 2023-10-27 | $586.00M derived: sum of 4 quarters · filed 2023-10-27 |
| 2022-07-03 | $202.00M 10-Q · filed 2023-07-31 | $270.00M 10-Q · filed 2023-07-31 | $378.00M derived: sum of 3 quarters · filed 2023-07-31 | $493.00M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-04-03 | $68.00M 10-Q · filed 2023-04-28 | $176.00M derived: sum of 2 quarters · filed 2023-04-28 | $291.00M derived: sum of 3 quarters · filed 2023-04-28 | $246.00M derived: sum of 4 quarters · filed 2023-04-28 |
| 2022-01-02 | $108.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $223.00M derived: sum of 2 quarters · filed 2023-02-16 | $178.00M derived: sum of 3 quarters · filed 2023-02-16 | $387.00M 10-K · filed 2023-02-16 |
| 2021-10-03 | $115.00M 10-Q · filed 2022-10-27 | $70.00M derived: sum of 2 quarters · filed 2022-10-27 | $279.00M 10-Q · filed 2022-10-27 | $23.00M derived: sum of 4 quarters · filed 2022-10-27 |
| 2021-07-04 | -$45.00M 10-Q · filed 2022-07-29 | $164.00M 10-Q · filed 2022-07-29 | -$92.00M derived: sum of 3 quarters · filed 2022-07-29 | -$261.00M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-04-04 | $209.00M 10-Q · filed 2022-04-29 | -$47.00M derived: sum of 2 quarters · filed 2022-04-29 | -$216.00M derived: sum of 3 quarters · filed 2022-04-29 | -$311.00M derived: sum of 4 quarters · filed 2022-04-29 |
| 2021-01-03 | -$256.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$425.00M derived: sum of 2 quarters · filed 2022-02-17 | -$520.00M derived: sum of 3 quarters · filed 2022-02-17 | -$473.00M 10-K · filed 2022-02-17 |
| 2020-09-27 | -$169.00M 10-Q · filed 2021-10-29 | -$264.00M derived: sum of 2 quarters · filed 2021-10-29 | -$217.00M 10-Q · filed 2021-10-29 | |
| 2020-06-28 | -$95.00M 10-Q · filed 2021-07-29 | -$48.00M 10-Q · filed 2021-07-29 | ||
| 2020-03-29 | $46.00M 10-Q · filed 2021-04-30 | |||
| 2019-09-29 | $162.00M 10-Q · filed 2020-10-23 | $105.00M derived: sum of 2 quarters · filed 2020-10-23 | $176.00M 10-Q · filed 2020-10-23 | |
| 2019-06-30 | -$57.00M 10-Q · filed 2020-07-24 | $14.00M 10-Q · filed 2020-07-24 | ||
| 2019-03-31 | $71.00M 10-Q · filed 2020-04-29 | |||
| 2018-09-30 | -$50.00M 10-Q · filed 2019-10-28 | $256.00M derived: sum of 2 quarters · filed 2019-10-28 | ||
| 2018-07-01 | $306.00M 10-Q · filed 2019-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |